824 related articles for article (PubMed ID: 28539325)
1. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.
Gomes-Silva D; Srinivasan M; Sharma S; Lee CM; Wagner DL; Davis TH; Rouce RH; Bao G; Brenner MK; Mamonkin M
Blood; 2017 Jul; 130(3):285-296. PubMed ID: 28539325
[TBL] [Abstract][Full Text] [Related]
2. An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies.
Cooper ML; Choi J; Staser K; Ritchey JK; Devenport JM; Eckardt K; Rettig MP; Wang B; Eissenberg LG; Ghobadi A; Gehrs LN; Prior JL; Achilefu S; Miller CA; Fronick CC; O'Neal J; Gao F; Weinstock DM; Gutierrez A; Fulton RS; DiPersio JF
Leukemia; 2018 Sep; 32(9):1970-1983. PubMed ID: 29483708
[TBL] [Abstract][Full Text] [Related]
3. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies.
Watanabe N; Mo F; Zheng R; Ma R; Bray VC; van Leeuwen DG; Sritabal-Ramirez J; Hu H; Wang S; Mehta B; Srinivasan M; Scherer LD; Zhang H; Thakkar SG; Hill LC; Heslop HE; Cheng C; Brenner MK; Mamonkin M
Mol Ther; 2023 Jan; 31(1):24-34. PubMed ID: 36086817
[TBL] [Abstract][Full Text] [Related]
4. Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection.
Jiang J; Chen J; Liao C; Duan Y; Wang Y; Shang K; Huang Y; Tang Y; Gao X; Gu Y; Sun J
Leukemia; 2023 Aug; 37(8):1660-1670. PubMed ID: 37391486
[TBL] [Abstract][Full Text] [Related]
5. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.
Chen KH; Wada M; Pinz KG; Liu H; Lin KW; Jares A; Firor AE; Shuai X; Salman H; Golightly M; Lan F; Senzel L; Leung EL; Jiang X; Ma Y
Leukemia; 2017 Oct; 31(10):2151-2160. PubMed ID: 28074066
[TBL] [Abstract][Full Text] [Related]
6. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
[TBL] [Abstract][Full Text] [Related]
7. Base-edited CAR T cells for combinational therapy against T cell malignancies.
Georgiadis C; Rasaiyaah J; Gkazi SA; Preece R; Etuk A; Christi A; Qasim W
Leukemia; 2021 Dec; 35(12):3466-3481. PubMed ID: 34035409
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia.
Xie L; Ma L; Liu S; Chang L; Wen F
Int Immunopharmacol; 2021 Jul; 96():107731. PubMed ID: 33965880
[TBL] [Abstract][Full Text] [Related]
9. Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
Pan J; Tan Y; Wang G; Deng B; Ling Z; Song W; Seery S; Zhang Y; Peng S; Xu J; Duan J; Wang Z; Yu X; Zheng Q; Xu X; Yuan Y; Yan F; Tian Z; Tang K; Zhang J; Chang AH; Feng X
J Clin Oncol; 2021 Oct; 39(30):3340-3351. PubMed ID: 34324392
[TBL] [Abstract][Full Text] [Related]
10. Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma.
Zhang M; Chen D; Fu X; Meng H; Nan F; Sun Z; Yu H; Zhang L; Li L; Li X; Wang X; Wang M; You F; Li Z; Chang Y; Zhou Z; Yan J; Li J; Wu X; Wang Y; Wang Y; Xiang S; Chen Y; Pan G; Xu H; Zhang B; Yang L
Clin Cancer Res; 2022 Jul; 28(13):2830-2843. PubMed ID: 35435984
[TBL] [Abstract][Full Text] [Related]
11. Universal Anti-CD7 CAR-T Cells Targeting T-ALL and Functional Analysis of CD7 Antigen on T/CAR-T Cells.
Xie L; Gu R; Yang X; Qiu S; Xu Y; Mou J; Wang Y; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Hum Gene Ther; 2023 Dec; 34(23-24):1257-1272. PubMed ID: 37861302
[TBL] [Abstract][Full Text] [Related]
12. CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia.
Gomes-Silva D; Atilla E; Atilla PA; Mo F; Tashiro H; Srinivasan M; Lulla P; Rouce RH; Cabral JMS; Ramos CA; Brenner MK; Mamonkin M
Mol Ther; 2019 Jan; 27(1):272-280. PubMed ID: 30391141
[TBL] [Abstract][Full Text] [Related]
13. CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy.
Kim MY; Cooper ML; Jacobs MT; Ritchey JK; Hollaway J; Fehniger TA; DiPersio JF
JCI Insight; 2021 Aug; 6(16):. PubMed ID: 34423790
[TBL] [Abstract][Full Text] [Related]
14. SECTM1-based CAR T cells enriched with CD7-low/negative subsets exhibit efficacy in CD7-positive malignancies.
Wei W; Ma H; Yang D; Sun B; Tang J; Zhu Y; Chen X; Huang X; Liu J; Hu Z; Liu T; Zou L; Zhao X
Blood Adv; 2023 Jul; 7(13):2941-2951. PubMed ID: 36848638
[TBL] [Abstract][Full Text] [Related]
15. Case report: Preventive infusion of donor-derived CD7 chimeric antigen receptor T cells after allogeneic hematopoietic stem cell transplantation.
Jiang Y; Feng D; Zhu J; Wei D; Zhao C; Liu H; Shao S; Wang C
Front Immunol; 2024; 15():1381308. PubMed ID: 38745670
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies.
Cooper ML; DiPersio JF
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101097. PubMed ID: 31779968
[TBL] [Abstract][Full Text] [Related]
17. Eradication of T-ALL Cells by CD7-targeted Universal CAR-T Cells and Initial Test of Ruxolitinib-based CRS Management.
Li S; Wang X; Yuan Z; Liu L; Luo L; Li Y; Wu K; Liu J; Yang C; Li Z; Wang D; Shen L; Ye X; He J; Han C; Wang Y; Zhang D; Dong Y; Fang L; Chen Y; Sersch M; Cao WW; Wang S
Clin Cancer Res; 2021 Mar; 27(5):1242-1246. PubMed ID: 33234511
[TBL] [Abstract][Full Text] [Related]
18. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
Front Immunol; 2019; 10():3123. PubMed ID: 32117200
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
20. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies.
Mamonkin M; Rouce RH; Tashiro H; Brenner MK
Blood; 2015 Aug; 126(8):983-92. PubMed ID: 26056165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]